As a result of more than 20 years of research by the scientists at the University of Tartu, the lactic acid bacteria strain ME-3, known for the last 15 years as the bacteria Hellus added to the dairy products of Tere, has now reached Estonia’s pharmacies.
ME-3 capsules were already sold in pharmacies all around Australia, the United Kingdom and Italy before reaching the shelves of Estonia’s pharmacies. The ME-3 bacterium is also added to the food supplement which normalises cholesterol levels, Reg´Activ Cholesterol, sold in 11 countries. The capsules now being sold in Estonia contain the strain in a pure and concentrated form; every capsule contains eight billion of Lactobacillus fermentum ME-3, which was discovered in 1995 from the intestine of a child from Tartu.
Marika Mikelsaar, professor emeritus at the University of Tartu (UT),together with Mihkel Zilmer, professor of medical biochemistry at UT, lead the workgroup that discovered the ME-3 strain. Last week, she visited the pharmacy of Tartu University Hospital to witness the fulfilment of a 20-year dream with her own eyes.
“At every conference, the most fascinating presenters are asked about their dreams. A scientist always spontaneously answers that their dream is to have their discovery put to use,” said Marika Mikelsaar.
She pointed out that, like with all basic research, in 1995, no one knew what the implications of the ME-3 strain would be. “If your goals in science were very targeted, then maybe it wouldn’t be real science,” she added.
According to her, ME-3 was something completely new compared to other probiotics known at the time. Mikelsaar recalls that in 2002 the World Health Organisation still defined probiotics as food supplements which influence and improve human microbiota.
“In 2010, a new definition was applied, according to which there are also probiotics that have targeted properties, the same way as ME 3 lowers cholesterol levels and improves cellular respiration. This is a class of its own,” said Mikelsaar.
The lactic bacterium ME-3 is a strain of human origin with well-described and scientifically-proved properties. It is the only strain in the world that has been patented for two useful effects –antimicrobial and antioxidant . Furthermore, research conducted in Estonia and abroad has shown that the ME-3 strain has health benefits, specifically it
• reproduces in the special conditions of the gastrointestinal tract,
• maintains and enriches the intestine’s microbiota by increasing the number of useful bacteria,
• enhances digestion,
• destroys harmful bacteria in the digestive tract,
• protects against the causes of intestinal infections,
• normalises the microbial balance of the digestive tract during and after treatment with antibiotics,
• reduces oxidative stress in the entire organism,
• lowers blood cholesterol levels and protects against vascular calcification,
• supports treatment of atopic dermatitis by suppressing inflammation.
Reg´Activ Essential ME-3 capsules are produced in France at VF Bioscience SAS. Jane Luht, head of technology transfer at the UT Centre for Entrepreneurship and Innovation, said that preparations are also being made for bringing the ME-3 capsules to the markets of Japan and the Republic of South Africa.
“Research and dissertations on ME-3 have been conducted and written at the University of Tartu for more than 20 years. It is pleasant that scientists are enthusiastic about further developing the applications of this bacterium,” Jane Luht commented on the UT’s most successful technology transfer project so far. “The use of ME-3 in dairy products and dietary supplements is not the only solution, we are also looking for possible applications in other areas.” According to Luht, ME-3 can be used, for example, in salad oil, chocolate, plant-based milks, as well as in cosmetics – all this requires further research with potential cooperation partners. “Initial information, however, is promising,” Luht added.
“ME-3 has been studied and protected at the University of Tartu for over 20 years. It’s good to see that scientists are enthusiastic and wish to further develop the bacterium’s applications,” commented Jane Luht when talking about the most successful technology transfer project at UT thus far.
“Using ME-3 in dairy products and in food supplements is not the only solution – we are also looking at opportunities for applications in other fields.” According to Luht, the ME-3 strain can be used, for example, in salad oils, chocolate, plant-based milks, and also in cosmetics. All this requires further research in cooperation with potential partners. “The initial data, however, looks promising,” added Luht.
In Estonia, the capsules are currently being sold in four pharmacies: the pharmacies of Mustamäe Health Centre, Arsenal Centre and Baltic Station Market in Tallinn and the Uus Apteek at the Tartu University Hospital.